Aliskiren/amlodipine/hydrochlorothiazide
| Combination of | |
|---|---|
| Aliskiren | Renin inhibitor |
| Amlodipine | Calcium channel blocker |
| Hydrochlorothiazide | Diuretic |
| Clinical data | |
| Trade names | Amturnide |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| PubChem CID | |
| KEGG | |
| Chemical and physical data | |
| Formula | C57H86Cl2N8O15S2 |
| Molar mass | 1258.38 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Aliskiren/amlodipine/hydrochlorothiazide, sold under the brand name Amturnide, is a fixed-dose combination medication that is used to treat high blood pressure.[1][2] It contains aliskiren, a renin inhibitor; amlodipine, as the besylate, a calcium channel blocker; and hydrochlorothiazide, a thiazide diuretic.[1] It is taken by mouth.[1]
It was approved for medical use in the United States in December 2010.[1][3][4] Amturnide was withdrawn by Novartis from the US market in 2017.[5]
References
- ^ a b c d e "Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets, for oral use Initial U.S. Approval: 2010". DailyMed. 10 November 2016. Retrieved 6 February 2022.
- ^ Neutel JM, Smith DH (October 2013). "Hypertension management: rationale for triple therapy based on mechanisms of action". Cardiovascular Therapeutics. 31 (5): 251–8. doi:10.1111/1755-5922.12015. PMID 23121769.
- ^ "Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets, for oral use Initial U.S. Approval: 2010". DailyMed. Retrieved 5 July 2024.
- ^ "Drug Approval Package: Amturnide(amlodipine/aliskiren/hydrochlorothiazide) NDA #200045". U.S. Food and Drug Administration (FDA). 15 August 2011. Retrieved 27 August 2020.
- Lay summary in: "Center for Drug Evaluation and Research: Application Number: 200045Orig1s000: Summary review" (PDF). Food and Drug Administration.
- ^ "Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications". Federal Register. 21 June 2017. Retrieved 6 February 2022.
External links
- "FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekturna)". U.S. Food and Drug Administration (FDA). 29 June 2021.
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |